Trial Profile
A Randomized, Double-Blind, Parallel Group, Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistent Asthma
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 08 Jun 2018
Price :
$35
*
At a glance
- Drugs Glycopyrrolate (Primary) ; Tiotropium bromide
- Indications Asthma
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 08 Jun 2018 New trial record